Spots Global Cancer Trial Database for young adults
Every month we try and update this database with for young adults cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection | NCT01445145 | Neoplasms | 16 Years - 30 Years | National Institutes of Health Clinical Center (CC) | ||
| MOST EMPOWER: Optimizing An Emotion Regulation Intervention | NCT04317417 | Cancer | EMPOWER | 15 Years - 39 Years | Wake Forest University Health Sciences | |
| Feasibility and Acceptability of a Virtual 'Coping With Brain Fog' Intervention for Young Adults With Cancer | NCT05115422 | Cancer Cognitive Dysfu... Cognitive Impai... Adolescents Young Adults | 'Coping with Br... | 18 Years - 40 Years | University of Manitoba | |
| Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors | NCT00502892 | Solid Tumors | Topotecan Ifosfamide Carboplatin | - 45 Years | M.D. Anderson Cancer Center | |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | NCT06289673 | Acute Lymphobla... Lymphoblastic L... Mixed Phenotype... | Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Tech-TYA: eHealth Platform to Deliver Group Intervention for YA Cancer Survivors | NCT05597228 | Cancer | Cognitive-Behav... | 18 Years - 39 Years | University of Arizona | |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma | NCT06289673 | Acute Lymphobla... Lymphoblastic L... Mixed Phenotype... | Dexamethasone Vincristine Daunorubicin Intrathecal tri... Methotrexate Cytarabine | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | NCT01884922 | Refractory Low-... Recurrent Low-g... | Nilotinib Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults | NCT01887522 | Refractory Low-... Recurrent Low-g... | Vinblastine + N... Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Feasibility and Acceptability of a Virtual 'Coping With Brain Fog' Intervention for Young Adults With Cancer | NCT05115422 | Cancer Cognitive Dysfu... Cognitive Impai... Adolescents Young Adults | 'Coping with Br... | 18 Years - 40 Years | University of Manitoba | |
| Revealing Information Genuinely & Honestly Across Time: Pediatric Oncology Stakeholder Preferences and Recommendations for Prognostic Communication | NCT05116566 | Pediatric Cance... Communication | 12 Years - | St. Jude Children's Research Hospital | ||
| Feasibility and Acceptability of a Virtual 'Coping With Brain Fog' Intervention for Young Adults With Cancer | NCT05115422 | Cancer Cognitive Dysfu... Cognitive Impai... Adolescents Young Adults | 'Coping with Br... | 18 Years - 40 Years | University of Manitoba | |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | NCT01884922 | Refractory Low-... Recurrent Low-g... | Nilotinib Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Needs Navigation for Caregivers of AYAs | NCT06296641 | Cancer in Adole... | Needs navigatio... | 15 Years - 26 Years | Columbia University | |
| Harnessing Generativity Among Young Adult Cancer Survivors | NCT04272346 | Cancer Young Adults | Writing for oth... Processing + wr... Facts-only writ... | 18 Years - 39 Years | University of California, Los Angeles | |
| Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | NCT01884922 | Refractory Low-... Recurrent Low-g... | Nilotinib Vinblastine | 6 Months - 20 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| Improving Symptom Self-management in Adolescents & Young Adults With Cancer | NCT02974569 | Symptom Cluster... Cancer | Computer Sympto... | 15 Years - 29 Years | Virginia Commonwealth University | |
| Digital Peer Navigation for Adolescents and Young Adults With Cancer | NCT06193369 | Lymphoma Breast Cancer Testicular Canc... Sarcoma | Digital Peer Na... | 18 Years - 40 Years | University Health Network, Toronto | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene | |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT04483778 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma Melanoma | second generati... second generati... Pembrolizumab | 0 Years - 26 Years | Seattle Children's Hospital | |
| Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors | NCT00502892 | Solid Tumors | Topotecan Ifosfamide Carboplatin | - 45 Years | M.D. Anderson Cancer Center | |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | NCT04972942 | T-cell Acute Ly... T-Cell Acute Ly... | Daratumumab | - 39 Years | New York Medical College | |
| Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity | NCT02664441 | Hypothalamic Ob... | Exenatide placebo | 10 Years - 25 Years | Seattle Children's Hospital | |
| Study of Oral Papillomavirus In Teens and Twenties | NCT00994019 | STD | 18 Years - 26 Years | Johns Hopkins Bloomberg School of Public Health | ||
| Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL | NCT06080191 | B-cell Acute Ly... | CD19-CAR_Lenti_... | 1 Year - 35 Years | Bambino Gesù Hospital and Research Institute | |
| Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | NCT02311621 | Neuroblastoma Ganglioneurobla... | Patient Derived... Patient Derived... Patient Derived... | 18 Months - 26 Years | Seattle Children's Hospital | |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | NCT05192889 | Refractory Acut... Relapsed Acute ... | Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation | 4 Years - 30 Years | St. Jude Children's Research Hospital | |
| Digital Peer Navigation for Adolescents and Young Adults With Cancer | NCT06193369 | Lymphoma Breast Cancer Testicular Canc... Sarcoma | Digital Peer Na... | 18 Years - 40 Years | University Health Network, Toronto | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | NCT02233049 | Diffuse Intrins... | Erlotinib Everolimus Dasatinib | 6 Months - 25 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | NCT05192889 | Refractory Acut... Relapsed Acute ... | Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation | 4 Years - 30 Years | St. Jude Children's Research Hospital | |
| Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children | NCT02308527 | Neuroblastoma | Bevacizumab Temozolomide Temozolomide Irinotecan Bevacizumab Topotecan Temozolomide Dinutuximab Bet... Cyclophosphamid... | 1 Year - 21 Years | University of Birmingham | |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | NCT03618381 | Pediatric Solid... Germ Cell Tumor Retinoblastoma Hepatoblastoma Wilms Tumor Rhabdoid Tumor Carcinoma Osteosarcoma Ewing Sarcoma Rhabdomyosarcom... Synovial Sarcom... Clear Cell Sarc... Malignant Perip... Desmoplastic Sm... Soft Tissue Sar... Neuroblastoma | second generati... second generati... | 1 Year - 30 Years | Seattle Children's Hospital | |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | NCT02233049 | Diffuse Intrins... | Erlotinib Everolimus Dasatinib | 6 Months - 25 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Undergraduate Skin Cancer Prevention Trial | NCT05634252 | Skin Cancer | Education Action Plan UV Photo MC1R Test | 18 Years - | University of Utah | |
| A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia. | NCT02450877 | Leukemia, Myelo... | Azacitidine Control Arm | 3 Months - 21 Years | Celgene | |
| Tech-TYA: eHealth Platform to Deliver Group Intervention for YA Cancer Survivors | NCT05597228 | Cancer | Cognitive-Behav... | 18 Years - 39 Years | University of Arizona | |
| A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | NCT03743246 | Precursor Cell ... Lymphoma, Non-H... | JCAR017 Lymphodepleting Fludarabine Cyclophosphamid... | - 25 Years | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
